Jerome J. Schentag
#126,396
Most Influential Person Now
Jerome J. Schentag's AcademicInfluence.com Rankings
Jerome J. Schentagmedical Degrees
Medical
#2021
World Rank
#2412
Historical Rank
Pharmacology
#205
World Rank
#245
Historical Rank
Download Badge
Medical Chemistry
Jerome J. Schentag's Degrees
- PhD Pharmaceutical Sciences University at Buffalo
- Bachelors Pharmacy University at Buffalo
Why Is Jerome J. Schentag Influential?
(Suggest an Edit or Addition)Jerome J. Schentag's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients (1993) (1114)
- Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections (2004) (717)
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. (2014) (675)
- Applied pharmacokinetics : principles of therapeutic drug monitoring (1986) (673)
- A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis (1991) (656)
- Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy (1998) (526)
- Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group (1994) (438)
- Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. (2003) (400)
- Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. (2008) (399)
- The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome (1995) (398)
- Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. (2004) (352)
- The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. (2005) (316)
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use Programme (2003) (274)
- Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. (1979) (259)
- Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid (2007) (238)
- Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia (2007) (231)
- Clinical experience with linezolid for the treatment of nocardia infection. (2003) (211)
- National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998-2003). (2007) (204)
- Tissue-directed pharmacokinetics. (1991) (193)
- Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin (1989) (182)
- Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response (1991) (177)
- Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. (1992) (175)
- Enhanced biotransformation of theophylline in marihuana and tobacco smokers (1978) (173)
- Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. (1991) (169)
- Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. (1989) (165)
- Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. (2000) (164)
- Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. (1998) (161)
- Increased gastric pH and the bioavailability of fluconazole and ketoconazole. (1991) (159)
- Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program (2003) (154)
- Mathematical Examination of Dual Individualization Principles (I): Relationships between AUC above MIC and Area under the Inhibitory Curve for Cefmenoxime, Ciprofloxacin, and Tobramycin (1991) (150)
- A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. (2002) (149)
- Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. (1998) (148)
- What have we learned from pharmacokinetic and pharmacodynamic theories? (2001) (145)
- Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. (1997) (142)
- Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin (1993) (137)
- Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning (1991) (136)
- Role for dual individualization with cefmenoxime. (1984) (135)
- Cefmenoxime efficacy, safety, and pharmacokinetics in critical care patients with nosocomial pneumonia. (1984) (135)
- Linezolid in the Treatment of Osteomyelitis: Results of Compassionate Use Experience (2004) (131)
- Alteration of theophylline clearance and half-life by cimetidine in normal volunteers. (1981) (130)
- In vitro selection of resistant Helicobacter pylori (1990) (128)
- Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. (2012) (128)
- Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. (1993) (126)
- Renal clearance and tissue accumulation of gentamicin (1977) (122)
- Effect of fluconazole on the disposition of phenytoin (1991) (120)
- Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. (2000) (112)
- Gentamicin tissue accumulation and nephrotoxic reactions. (1978) (109)
- Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. (1999) (103)
- Factors Associated With Postoperative Infection (2001) (103)
- Tissue persistence of gentamicin in man. (1977) (100)
- Intravenous theophylline therapy: nomogram guidelines. (1977) (100)
- Inhibition of enoxacin absorption by antacids or ranitidine (1989) (97)
- Sucralfate reduces the gastrointestinal absorption of norfloxacin (1989) (93)
- Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. (2000) (93)
- Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients (1981) (91)
- Dose and serum concentration relationships in cimetidine-associated mental confusion. (1980) (90)
- Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients (1981) (89)
- Effects of ranitidine and sucralfate on ketoconazole bioavailability (1991) (89)
- Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. (1978) (87)
- Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers (1995) (86)
- Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar (1994) (84)
- Aminoglycoside nephrotoxicity in critically iii surgical patients (1979) (83)
- Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin (2004) (83)
- Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. (1998) (82)
- The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. (2002) (80)
- Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. (1990) (80)
- Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. (1996) (78)
- Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials (2003) (78)
- Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides. (1980) (77)
- Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. (1987) (74)
- Clinical Significance of Antibiotic Tissue Penetration (1989) (73)
- Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates (2003) (73)
- Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit (2001) (73)
- Accumulation Pharmacokinetics of Tobramycin (1978) (71)
- Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. (2003) (71)
- Liquid-chromatographic determination of ciprofloxacin in serum and urine. (1985) (70)
- Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients (1982) (69)
- NEW 4-ARYL-1,4-DIHYDROPYRIDINES AND 4-ARYLPYRIDINES AS P-GLYCOPROTEIN INHIBITORS (2005) (67)
- Achieving an Optimal Outcome in the Treatment of Infections (1999) (65)
- Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. (2001) (64)
- A Randomized Clinical Trial of Moxalactam Alone versus Tobramycin plus Clindamycin in Abdominal Sepsis (1983) (63)
- Comparison of the Fluoroquinolones Based on Pharmacokinetic and Pharmacodynamic Parameters (2000) (63)
- Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. (1999) (63)
- Economic consequences of antimicrobial resistance. (2002) (60)
- Liquid-chromatographic determination of cimetidine, its known metabolites, and creatinine in serum and urine. (1981) (59)
- The Quinolones: An Overview and Comparative Appraisal of Their Pharmacokinetics and Pharmacodynamics (1988) (59)
- Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. (1985) (57)
- Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area under the Inhibitory Curve is More Rapid for Ciprofloxacin Than for Cefmenoxime (1994) (56)
- Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis (1989) (56)
- Opportunities for Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development (1992) (56)
- Pharmacokinetics of ceftazidime in patients with renal insufficiency (1984) (55)
- Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects (1987) (55)
- Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates. (1980) (54)
- Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides (1979) (54)
- Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. (1995) (54)
- Pharmacodynamic interactions of antibiotics alone and in combination. (1998) (54)
- System for clinical pharmacokinetic monitoring of theophylline therapy. (1976) (51)
- Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. (1986) (50)
- Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics. (1985) (49)
- Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli (1988) (49)
- Clinical Use of Ceftriaxone (2001) (48)
- Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. (1984) (48)
- Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients: Magnitude and predictability of interindividual differences * (1980) (48)
- Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects (2007) (47)
- AUIC — The Universal Parameter within the Constraint of a Reasonable Dosing Interval (1996) (47)
- Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. (1983) (45)
- C-reactive protein as an indicator of infection relapse in patients with abdominal sepsis. (1984) (45)
- Mental Status, the Intensive Care Unit, and Cimetidine (1982) (44)
- The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions (1993) (44)
- Clinical and Economic Impact of Oral Ciprofloxacin as Follow-up to Parenteral Antibiotics (1991) (44)
- Noncompartmental determination of the steady-state volume of distribution during multiple dosing. (1984) (42)
- Pharmacodynamic Modeling of Risk Factors for Ciprofloxacin Resistance in Pseudomonas aeruginosa (2000) (42)
- Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae. (1999) (41)
- Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. (2003) (41)
- Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. (1987) (40)
- Comparative tissue accumulation of gentamicin and tobramycin in patients. (1978) (40)
- In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa (1995) (39)
- Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients. (1979) (38)
- Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients (1981) (38)
- Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. (2000) (38)
- Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. (1997) (37)
- Determinants of Antibiotic‐associated Hypoprothrombinemia (1987) (35)
- New turbidimetric assay for quantitation of viable bacterial densities (1993) (35)
- Excessive aminoglycoside nephrotoxicity in obese patients. (1988) (35)
- Two-compartment gentamicin pharmacokinetics in premature neonates: a comparison to adults with decreased glomerular filtration rates. (1980) (34)
- Antibiotic dosing--does one size fit all? (1998) (34)
- Intoxication caused by interaction of chloramphenicol and phenytoin. (1977) (34)
- Effect of lomefloxacin on theophylline pharmacokinetics (1989) (34)
- Sparfloxacin: a review. (2000) (33)
- Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. (2014) (33)
- Dose-Ranging Pharmacokinetic Study of Ciprofloxacin after 200-, 300-, and 400-mg Intravenous Doses (1992) (33)
- Budget Impact Analysis of Rapid Screening for Staphylococcus aureus Colonization Among Patients Undergoing Elective Surgery in US Hospitals (2008) (33)
- Effects of enteral and intravenous antimicrobial treatment on survival following intestinal ischemia in rats. (1989) (33)
- Removal of Cimetidine by Peritoneal Dialysis, Hemodialysis, and Charcoal Hemoperfusion (1980) (32)
- Cimetidine‐Associated Mental Confusion: Further Studies in 36 Severely Ill Patients (1980) (29)
- A Case Series of Macrolide Treatment Failures in Community Acquired Pneumonia (2007) (29)
- Effect of gastric acidity on enoxacin absorption (1992) (29)
- Pharmacokinetics and metabolism of moxifloxacin. (2000) (29)
- Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. (1987) (29)
- In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. (1997) (29)
- Once‐Daily Cefepime Versus Ceftriaxone for Nursing Home–Acquired Pneumonia (2007) (28)
- Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions (1980) (28)
- Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers (1987) (28)
- Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. (2002) (27)
- Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline (1989) (27)
- Gentamicin disposition and tissue accumulation on multiple dosing (1977) (27)
- Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin. (1985) (27)
- Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. (1999) (27)
- Degradation kinetics of imipenem in normal saline and in human serum (1986) (27)
- Pharmacodynamic Modeling of Bacterial Kinetics: β‐Lactam Antibiotics against Escherichia colj (1994) (27)
- Principles of antibiotic tissue penetration and guidelines for pharmacokinetic analysis. (1982) (26)
- Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. (2000) (26)
- Fluoroquinolone pharmacodynamics. Authors' reply (2001) (26)
- Pharmacokinetics and nephrotoxicity of continuous intravenous infusion of gentamicin in low birth weight infants. (1986) (26)
- Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study. (2007) (26)
- Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis (1988) (26)
- Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. (1999) (26)
- Pharmacokinetics of lomefloxacin in renally compromised patients (1990) (25)
- Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia. (2006) (24)
- Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin Resistant Staphylococcus aureus (2014) (23)
- Therapeutic Monitoring of Aminoglycoside Antibiotics: An Approach (1980) (23)
- Mental Confusion in a Patient Treated with Metronidazole — A Concentration‐Related Effect? (1982) (23)
- Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients. (1999) (23)
- Clinical Experience With Linezolid in Conjunction With Wound Coverage Techniques for Skin and Soft-Tissue Infections and Postoperative Osteomyelitis (2004) (22)
- A Clinical Pharmacy-Oriented Drug Surveillance Network: I. Program Description (1987) (22)
- High-pressure liquid chromatography analysis and single-dose disposition of tobramycin in human volunteers (1980) (22)
- Ranitidine disposition and systemic availability in hepatic cirrhosis (1984) (22)
- Rate of methicillin penetration into normal heart valve and experimental endocarditis lesions (1982) (22)
- Interaction Between Ciprofloxacin and Metal Cations: Its Influence on Physicochemical Characteristics and Antibacterial Activity (1994) (22)
- Single-dose cefmetazole versus multiple dose cefoxitin for prophylaxis in abdominal surgery. (1989) (22)
- Possible alteration of metronidazole metabolism by phenobarbital. (1982) (21)
- Effect of protein binding on cefmenoxime steady‐state kinetics in critical patients (1984) (21)
- Prospective Surveillance of Antibiotic‐Associated Coagulopathy in 970 Patients (1989) (21)
- Costs of treating lower respiratory tract infections. (2008) (21)
- The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. (1988) (20)
- Potential Role of Pharmacokinetics, Pharmacodynamics, and Computerized Databases in Controlling Bacterial Resistance (2000) (19)
- Use of Benchmarking Techniques to Justify the Evolution of Antibiotic Management Programs in Healthcare Systems (1995) (19)
- Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. (1988) (19)
- Kinetics and action of N-methylthiotetrazole in volunteers and patients. Population-based clinical comparisons of antibiotics with and without this moiety. (1988) (19)
- Two-compartment comparison of gentamicin and tobramycin in normal volunteers (1982) (19)
- Assessment of the Enzymuria Resulting from Gentamicin Alone and Combinations of Gentamicin with Various β-Lactam Antibiotics (1997) (18)
- Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. (2003) (18)
- Cefmetazole Sodium: Pharmacology, Pharmacokinetics, and Clinical Trials (1991) (18)
- Specificity of Renal Tubular Damage Criteria for Aminoglycoside Nephrotoxicity in Critically III Patients (1983) (17)
- Renal Tubular Enzyme Effects of Clarithromycin in Comparison with Gentamicin and Placebo in Volunteers (1992) (17)
- Quinolone pharmacokinetics in the elderly. (1992) (17)
- Methicillin distribution in serum and extravascular fluid and its relevance to normal and damaged heart valves (1981) (17)
- In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. (1998) (16)
- Cimetidine in Systemic Mastocytosis (1981) (16)
- Understanding and managing microbial resistance in institutional settings. (1995) (16)
- A Specific and Sensitive High Pressure Liquid Chromatographic Procedure for Cimetidine and Creatinine (1979) (16)
- Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers (1997) (16)
- Fetal uptake and neonatal disposition of procainamide and its acetylated metabolite: a case report. (1978) (16)
- Pharmacokinetics and safety of tamsulosin in subjects with normal and impaired renal or hepatic function (2001) (15)
- Cimetidine kinetics during resuscitation from burn shock (1984) (15)
- Population Pharmacokinetic Methods to Optimise Antibiotic Effects (1993) (15)
- The Increase in Urinary Alanine Aminopeptidase Excretion Associated with Enflurane Anesthesia Is Increased Further by Aminoglycosides (1988) (15)
- SARS: CLEARING THE AIR (2004) (15)
- Predicted tissue accumulation of netilmicin in patients (1981) (15)
- A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. (2009) (14)
- Role of pharmacokinetics and pharmacodynamics in the design of dosage schedules for 12-h cefotaxime alone and in combination with other antibiotics. (1995) (14)
- HPLC determination of D and L moxalactam in human serum and urine. (1982) (14)
- Pharmacokinetics of capacity-limited tissue distribution of methicillin in rabbits. (1984) (14)
- The partitioning of cimetidine into canine cerebrospinal fluid. (1984) (14)
- Excretion of cephalothin and cefamandole by the normal pancreas and in acute pancreatitis in dogs (1982) (13)
- The pharmacokinetics and metabolism of cimetidine in neonates. (1984) (13)
- Pharmacodynamic modeling of bacterial kinetics: beta-lactam antibiotics against Escherichia coli. (1994) (13)
- Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens. (1987) (13)
- Direct Costs in Patients Hospitalised with Community-Acquired Pneumonia After Non-Response to Outpatient Treatment with Macrolide Antibacterials in the US (2012) (13)
- Modeling the response of pneumonia to antimicrobial therapy (1997) (13)
- Population pharmacokinetics of levofloxacin in Korean patients (2016) (12)
- Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone. (2000) (12)
- Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges. (1992) (12)
- Influence of extended-spectrum beta-lactams on gram-negative bacterial resistance. (2008) (12)
- Allopurinol sensitivity: report of two cases. (1979) (11)
- Antibiotic selection and dosing for the treatment of acute exacerbations of COPD. (1997) (11)
- Distribution of cimetidine in postmortem tissues. (1984) (11)
- Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole (1990) (11)
- Mathematical Examination of Dual Individualization Principles (III): Development of a Scoring System for Pneumonia Staging and Quantitation of Response to Antibiotics: Results in Cefmenoxime-Treated Patients (1992) (11)
- Effect of Food on the Oral Bioavailability of Isosorbide‐5‐Mononitrate Administered as an Extended‐Release Tablet (1995) (11)
- Antibiotic penetration in liver infection: a case of tobramycin failure responsive to moxalactam. (1983) (11)
- Observations on vancomycin use in U.S. hospitals. (2007) (11)
- The results of a targeted pharmacy intervention program. (1993) (10)
- Cefmenoxime in the treatment of nosocomial pneumonias in critical care patients. (1984) (10)
- Effect of Concomitant Administration of Cimetidine Hydrochloride on the Pharmacokinetic and Safety Profile of Tamsulosin Hydrochloride 0.4 mg in Healthy Subjects (2002) (10)
- Impact of Disease States on the Pharmacokinetics and Pharmacodynamics of Angiotensin‐Converting Enzyme Inhibitors (2006) (10)
- Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy. (1998) (10)
- Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. (1985) (10)
- Creatinine clearance predictions in acutely ill patients. (1981) (10)
- Rebound following hemodialysis of cimetidine and its metabolites. (1984) (9)
- A Microcomputer Program for Tobramycin Consult Services, Based on the Two-Compartment Pharmacokinetic Model (1983) (9)
- A Clinical Pharmacy-Oriented Drug Surveillance Network: II. Results of a Pilot Project (1987) (9)
- Effect of Bile induced Pancreatitis on Tobramycin Excretion in Pancreatic Fluid (1981) (9)
- Liquid-chromatographic assay of cefmenoxime in serum and urine. (1983) (9)
- Antibiotic treatment of acute otitis media in children: dosing considerations (1995) (9)
- The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers. (1995) (9)
- Effects of the Concomitant Administration of Tamsulosin (0.8 mg/Day) on the Pharmacokinetic and Safety Profile of Theophylline (5 mg/kg): A Placebo-Controlled Evaluation (2002) (9)
- False-positive "hemoccult" reaction with cimetidine. (1980) (8)
- Assessing Antibacterial Pharmacoeconomics in the Intensive Care Unit (1997) (8)
- Safety and Acid-Suppressant Properties of Histamine2-Receptor Antagonists for the Prevention of Stress-Related Mucosal Damage in Critical Care Patients (1989) (8)
- Effects of the concomitant administration of tamsulosin (0·8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin®) in normal healthy subjects: a placebo‐controlled evaluation (2002) (8)
- What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia. (2008) (8)
- Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers (1990) (8)
- Comparison of N-methylthiotetrazole dispositions in healthy volunteers following single intravenous doses of moxalactam, cefoperazone, and cefotetan (1989) (8)
- In vitro interactions between beta-lactam antibiotics and tobramycin. (1981) (8)
- Changing the Infection Control Paradigm From Off-Line to Real Time The Experience at Millard Fillmore Health System (1997) (8)
- Kinetics and dynamics of tobramycin action in patients with bacteriuria given single doses (1991) (8)
- The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: Age related differences as compared to adults (2004) (8)
- Correlations between Microbiological Outcomes and Clinical Responses in Patients with Severe Pneumonia (2013) (8)
- Obesity as a risk factor in drug-induced organ injury. V. Toxicokinetics of gentamicin in the obese overfed rat. (1992) (7)
- The Effect of Verapamil on the Nephrotoxic Potential of Gentamicin as Measured by Urinary Enzyme Excretion in Healthy Volunteers (1995) (7)
- A Clinical Pharmacy-Oriented Drug Surveillance Network: Results of a Nationwide Antibiotic Utilization Review of Bacterial Pneumonia–1987 (1989) (7)
- Ampicillin‐Sulbactam versus Cefoxitin for Prophylaxis in High‐Risk Patients Undergoing Abdominal Surgery (1994) (7)
- CRITICAL CARE PATIENTS WITH SIGNIFICANT, RESISTANT, GRAM-POSTIVE INFECTIONS ENROLLED IN THE LINEZOLID COMPASSIONATE USE PROTOCOL (1999) (7)
- The Effect of Low‐Dose Cimetidine (200 mg Twice Daily) on the Pharmacokinetics of Theophylline (1999) (7)
- Hepatic encephalopathy and altered cimetidine kinetics (1983) (6)
- Cimetidine bioavailability after massive small bowel resection. (1982) (6)
- Pharmacodynamics and kinetics of cimetidine in a premature newborn. (1983) (6)
- Antibiotic Penetration in Abdominal Infection: A Case of Tobramycin Failure Responsive to Moxalactam (1983) (6)
- Performance of the fractional maximal effect method: comparative interaction studies of ciprofloxacin and protein synthesis inhibitors. (1996) (6)
- Determination of Cefmenoxime in Human Serum by Ion-Pair Reverse-Phase High Performance Liquid Chromatography (1985) (6)
- Failure of cimetidine in Zollinger-Ellison syndrome (1983) (6)
- Neutropenia associated with beta-lactam antibiotics. (1983) (6)
- The economics of Clostridium difficile-associated disease for providers and payers. (2008) (6)
- ICU nurses rate their work places. (1981) (5)
- Principles of Antibiotic Tissue Penetration and Guidelines for Pharmacokinetic Analysis (1982) (5)
- Glucose Supply and Insulin Demand Dynamics of Antidiabetic Agents (2010) (5)
- A Rapid, Universal TI-59 Model-Independent Pharmacokinetic Analysis Program based on Statistical Moment Theory (1985) (5)
- A model for the prospective identification of the prenephrotoxic state during gentamicin therapy (1978) (5)
- Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System. (1997) (4)
- Pharmacodynamic Interactions of Ciprofloxacin, Piperacillin, and Piperacillin/Tazobactam in Healthy Volunteers (1998) (4)
- Impact of Organism Species on Microbial Eradication and Development of Resistance in Severe Gram-Negative Pneumonia (2010) (4)
- Costs of Treating Lower Respiratory Tract Infections in Outpatients (2008) (4)
- Structures and biological activities of tobramycin-ticarcillin adducts. (1994) (4)
- The Economic Potential of Dual Individualisation Methodologies (1996) (3)
- Renal handling of gentamicin by normal and ischemic canine kidneys. (1982) (3)
- The Relationship Between Ciprofloxacin Blood Concentrations, MIC Values, Bacterial Eradication, and Clinical Outcome in Patients with Nosocomial Pneumonia (1994) (3)
- Application of Dual Radiotelemetric Technique in Studying Drug–Drug Interaction Between Diclofenac Sodium and Ranitidine HCl in Volunteers (1993) (3)
- Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease. (1993) (3)
- An integrated epidemiological and neural net model of the warfarin effect in managed care patients (2017) (3)
- Complexation versus Hemodialysis To Reduce Elevated Aminoglycoside Serum Concentrations (1984) (3)
- Effect of metronidazole on theophylline pharmacokinetics. (1983) (3)
- Repeated oral doses of activated charcoal and the clearance of tobramycin, a non-absorbable drug. (1987) (3)
- Assessment of Pharmacokinetic Drug Interactions in Clinical Drug Development (1993) (2)
- Lack of Effect of Piroxicam on Theophylline Clearance in Healthy Volunteers (1990) (2)
- Clinical Research: Cimetidine in the Prophylaxis of Stress Ulceration in Severely Burned Patients (1983) (2)
- Steady-state moxalactam pharmacokinetics in patients: Noncompartmental versus two-compartmental analysis (1983) (2)
- Estimation of the Steady-State Volume of Distribution for Digoxin: A Comparison of Model-Independent Methods with a Two-Compartment Model in Healthy Volunteers (1985) (2)
- Moxalactam penetration into normal heart valve, cardiac vegetations, and myocardium in relation to protein binding and physiological distribution spaces (1984) (2)
- No false "Hemoccult" reaction with ranitidine. (1984) (2)
- Characterization of Cardiovascular Outcomes in a Type 2 Diabetes Glucose Supply and Insulin Demand Model (2010) (1)
- Abbreviating the Duration of Intravenous Antibiotics with Oral Fluoroquinolones (1993) (1)
- Pharmacodynamic interactions of ciprofloxacin , piperacillin , and piperacillin/tazobactam in volunteer subjects (1994) (1)
- Structures and Biological Activities of Tobramycin‐Ticarcillin Adducts. (2010) (1)
- [Aminoglycoside tissue accumulation. A comparison between gentamycin and tobramycin in patients (author's transl)]. (1978) (1)
- 1013-P: Modification of Inflammatory and Alzheimer Markers with Intracellular Delivery of Insulin Using Cholestosomes (2020) (1)
- P284 Prospective multicenter trial of tigecycline for treatment of central venous catheter (CVC)-related coagulase-negative staphylococcal (CoNS) bacteremia (2009) (1)
- Cimetidine-induced mental confusion in patients with cirrhosis. (1980) (1)
- C-REACTIVE PROTEIN AS AN INDICATOR INFECTION RELAPSE IN PATIENTS WITH ABDOMINAL SEPSIS (1984) (1)
- Establishing Criteria for Assessment of Efficacy of Antimicrobial Agents in Acute Otitis Media (2000) (1)
- A new model for bacterial growth & drug effects (1999) (1)
- Chapter 7 – Antibiotics in the ICU (2006) (1)
- Pharmacodynamics of Bolus Famotidine Versus Infused Cimetidine, Ranitidine, and Famotidine (1994) (1)
- Dispositif et procédés de surveillance d'un individu in vivo (2011) (0)
- Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response (2022) (0)
- Effect ofBileInducedPancreatitis on Tobramycin Excretion inPancreatic Fluid (1980) (0)
- Zusammensetzungen und verfahren zur behandlung und diagnose von leberverfettung allein oder in kombination mit einer hepatitis-c-virusinfektion (2012) (0)
- PIN22 IMPACT OF S.AUREUS INFECTIONS ON EXPENDITURES AND LENGTH-OF-STAY IN U.S. HOSPITALS (2007) (0)
- Books Received (2005) (0)
- Ciprofloxacin Eradicates Respiratory Tract Bacteria More Rapidly than Cephalosporins in Patients with Nosocomial Pneumonia (1993) (0)
- Liquid-ChromatographicDeterminationof Ciprofloxacinin Serum and Urine (1985) (0)
- Sa1362 Comparison of Weight and Metabolic Profiles in Patients Treated With an Oral Mimetic of the Roux-en-Y Gastric Bypass Effect (2014) (0)
- The Development of a Bedside Algorithm Capable of Targeting Anti‐Endotoxins to the Responder Subpopulations (1993) (0)
- Role of a management team in improving ace inhibitor dosing for heart failure (1999) (0)
- Mimétiques de formulations orales d'actions de bypass gastrique roux-en-y sur le frein iléal ; compositions, procédés de traitement, diagnostics et systèmes pour le traitement de manifestations de syndrome métabolique comprenant l'insulino-résistance, la stéatose hépatique, l'hyperlipidémie et t2d (2012) (0)
- P5 Predictors for time to improvement in community-acquired pneumonia: pharmacodynamic correlation with time to treatment response (2009) (0)
- O68 Hospitalization and economics of PK/PD treatment of acute exacerbation of chronic bronchitis (AECB) (2009) (0)
- PROLONGED DETECTION OF GENTAMICIN IN NEONATES FOLLOWING CESSATION OF THERAPY (1977) (0)
- Pharmacokinetics ofAmpicillin (2.0Grams)andSulbactam (1.0 Gram)Coadministered toSubjects withNormalandAbnormalRenal Function andwithEnd-Stage RenalDisease on Hemodialysis (1989) (0)
- A pharmacometric model for factors in the development of bacterial resistance in acutely ill patients (1997) (0)
- Grepafloxacin in Patients with Acute Bacterial Exacerbations of Chronic Bronchitis - a Question of Speed in Bacterial Killing (1998) (0)
- viable bacterial densities. New turbidimetric assay for quantitation of (2013) (0)
- Multiple dose pharmacokinetics pks of po opc 17116 in normal subjects 400 vs 800 mg parallel design (1992) (0)
- Mo1566 A Neural Net Model for Pediatric and Adult NAFLD and NASH Using Health Records: Comparison With Type 2 Diabetes Patients and Predicted Beneficial Treatment of Both Components of Metabolic Syndrome With an Oral Mimetic of Roux-en-Y Gastric Bypass (2016) (0)
- PHARMACODYNAMIC RATIONALE FOR SELECTING THE FLUOROQUINOLONES (1999) (0)
- Comparison ofTwoMethods forDetermining InVitro Postantibiotic Effects ofThreeAntibiotics on Escherichia coli (1988) (0)
- Capsule et methode de telemesure (1992) (0)
- Optimizing antimicrobial therapy in respiratory-tract infections: new agents, new strategies. Introduction. (1999) (0)
- Impact of clinical pharmacist‐based intervention on outcomes in CHF (1999) (0)
- O69 Modeling H. influenzae treatment response and progression in patients with COPD as they progress between acute exacerbation of chronic bronchitis (AECB) and community acquired pneumonia (CAP) (2009) (0)
- PD Modeling of Three Chemotherapeutic Agents and Human Lung Tumor Cells (1999) (0)
- MINIREVIEW Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid (cid:1) (2007) (0)
- Hospital and Regional Variations in S. aureus Infection Prevalence and Outcomes in the US (2007) (0)
- The comparative in vitro activities of three quinolones against clinical Streptococcus pneumoniae isolates (2006) (0)
- Einfluß von Schwangerschaft und Aufteilung der Tagesdosis auf die Ototoxizität und Nephrotoxizität von Tobramycin (1981) (0)
- Vorrichtung und verfahren zur in-vivo-überwachung von patienten (2011) (0)
- Antibiotic Pharmacokinetics and Pharmacodynamics: How Can They Be Used to Optimize Therapy in Ventilator-Associated Pneumonia? (2005) (0)
- P9 Examination of AUICs for Streptococcus pneumoniae (SP) in patients with CAP failing to respond to outpatient β-lactams (BL) (2009) (0)
- Pharmacokinetics and pharmacodynamics as they apply to the lung (2006) (0)
- Stichprobenkapsel und Verfahren (1995) (0)
- Aminoglycoside Nephrotoxicity in 201 Critically Ill Patients (0)
- Relationships between serum, intracellular, and infection site concentrations of macrolide and azalide antibiotics: A theoretical exploration of the concept of white blood cell drug delivery to infection sites (1996) (0)
- Pharmacometric modelling of risk factors for MRSA (1997) (0)
- Antibody to endotoxin in the treatment of gram-negative sepsis. (1992) (0)
- Administration ciblée d'organismes probiotiques et/ou d'agents thérapeutiques dans le tractus gastro-intestinal (2014) (0)
- MINIREVIEWS Antibiotic Tissue Penetration and Its Relevance: Models of Tissue Penetration and Their Meaning (0)
- absorption of norfloxacin. Sucralfate reduces the gastrointestinal (2013) (0)
- Benchmarking in health-system pharmacy: Establishing and justifying antimicrobial management programs (2000) (0)
- A DOUBLE‐BLIND, RANDOMIZED COMPARISON OF AZTREONAM PLUS CLINDAMYCIN WITH TOBRAMYCIN PLUS CLINDAMYCIN IN ABDOMINAL INFECTIONS (1995) (0)
- Methicillin Distribution inSerumandExtravascular Fluid and ItsRelevance toNormalandDamagedHeartValves (1981) (0)
- Mini-Reviews — Pharmacokinetics/Pharmacodynamics (PK/PD) (2000) (0)
- Costs and bacterial susceptibility after therapeutic interchange of fluoroquinolones (2000) (0)
- studies in 201 patients. pharmacokinetic and clinical gentamicin and tobramycin: Comparative nephrotoxicity of (2014) (0)
- COST-EFFECTIVENESS ANALYSIS OF NEUROMUSCULAR BLOCKING AGENTS (NMBAs) USED IN THE INTENSIVE CARE UNITS (1999) (0)
- P&T Committee review of fluconazole: an effective alternative to antifungal therapy. (1990) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jerome J. Schentag?
Jerome J. Schentag is affiliated with the following schools:
